Abstract
Bevacizumab-containing therapies can improve outcomes in patients with sarcoma. Bevacizumab had several notable adverse effects including bowel perforation but bilateral pneumothorax had never been reported in the available English literature. We reported a 23-year-old male with poorly differentiated fibrosarcoma who had spontaneous bilateral spontaneous pneumothorax (SP) after the third cycle of bevacizumab-containing chemotherapy. His bilateral pneumothorax resolved after closed drainage of pleural cavity with a small caliber catheter. The mechanism of pneumothorax developed after bevacizumab therapy was not clear. In patients who had chest discomfort after bevacizumab-containing therapy, pneumothorax should never be overlooked as one of the differential diagnoses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
